217 related articles for article (PubMed ID: 32871847)
1. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Smetana K; Rosel D; BrÁbek J
In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
[TBL] [Abstract][Full Text] [Related]
2. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
3. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
4. What is the role of rheumatologists in the era of COVID-19?
Marotto D; Sarzi-Puttini P
Autoimmun Rev; 2020 Jun; 19(6):102539. PubMed ID: 32251716
[No Abstract] [Full Text] [Related]
5. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
8. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
10. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
11. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.
Quesada-Gomez JM; Entrenas-Castillo M; Bouillon R
J Steroid Biochem Mol Biol; 2020 Sep; 202():105719. PubMed ID: 32535032
[TBL] [Abstract][Full Text] [Related]
13. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
16. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.
Convertino I; Tuccori M; Ferraro S; Valdiserra G; Cappello E; Focosi D; Blandizzi C
Crit Care; 2020 Jun; 24(1):331. PubMed ID: 32527304
[TBL] [Abstract][Full Text] [Related]
17. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
18. Can Glycine Mitigate COVID-19 Associated Tissue Damage and Cytokine Storm?
Li CY
Radiat Res; 2020 Sep; 194(3):199-201. PubMed ID: 32942307
[No Abstract] [Full Text] [Related]
19. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
Bendjelid K; Giraud R; Von Düring S
Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550
[No Abstract] [Full Text] [Related]
20. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.
Wu C; Hou D; Du C; Cai Y; Zheng J; Xu J; Chen X; Chen C; Hu X; Zhang Y; Song J; Wang L; Chao YC; Feng Y; Xiong W; Chen D; Zhong M; Hu J; Jiang J; Bai C; Zhou X; Xu J; Song Y; Gong F
Crit Care; 2020 Nov; 24(1):643. PubMed ID: 33172477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
